Plotkin Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Plotkin Financial Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,653	Closed	-$224K	–	104
2021 Q2	$224K	Hold	1,653	–	–	0.12%	89
2021 Q1	$224K	Buy	+1,653	New	+$247K	0.14%	70

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Plotkin Financial Advisors's XBI Position: Q3 2021 in Review

Plotkin Financial Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 1,653 shares — an estimated $224K sold.

Plotkin Financial Advisors first reported a position in XBI in Q1 2021 and held it in 2 quarters. The position peaked at $224K in Q1 2021. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

Plotkin Financial Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
Plotkin Financial Advisors sold 1,653 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $224K.
Plotkin Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 2 quarters.
Plotkin Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $224K in Q1 2021.
635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Plotkin Financial Advisors's 13F filing for Q3 2021, filed 15 Nov 2024.